The project DualmAb has been selected by the Agence Nationale de la Recherche (ANR) and will be funded from 2020. This projects aims at developping PET-fluorescence bimodal antibodies targeting endothelin 1 receptors, in order to reveal glioblastoma for either diagnosis (PET) or surgery (fluorescence).
This project, led by Franck Denat from the ICMUB, Dijon, will involve several other academic partners (CEA, Inserm) from different regions (Paris area, Dijon, Montpellier), as well as the company Kaer Labs, which will develop a high resolution in vivo fluorescence imaging system for the project. We are proud to be part of the project and looking forward the collaboration with the different laboratories involved in DualmAb.
